HSBC maintains buy on AbbVie, raises target to $315
Benzinga/TradingView reports that HSBC raised its AbbVie price target to $315 from $300 and maintained a Buy rating.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.